Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4

Affiliation auteurs!!!! Error affiliation !!!!
TitreEverolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4
Type de publicationJournal Article
Year of Publication2017
AuteursBachelot T., Royce M., Villanueva C., F. Cruz M, Hegg R., Falkson C., Jeong J., Srimuninnimit V., Arce C.H, Ridolfi A., Lin C., Gradishar W., Ozguroglu M., Cardoso F., Azevedo S.
JournalANNALS OF ONCOLOGY
Volume28
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534